Previous 10 | Next 10 |
Mersana Therapeutics, Inc. (MRSN) Q3 2019 Earnings Conference Call November 06, 2019, 08:00 ET Company Participants Sarah Carmody - Executive Director, IR & Corporate Communications Anna Protopapas - President, CEO & Director Dirk Huebner - Chief Medical Officer Timothy...
CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented...
Mersana Therapeutics (NASDAQ: MRSN ): Q3 GAAP EPS of -$0.35 beats by $0.02 . More news on: Mersana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
XMT-1536 Expansion Study Continues According to Plan Ended Third Quarter 2019 with $112 Million Available to Fund the Advancement of Multiple Product Candidates CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmac...
Gainers : Camber Energy (NYSEMKT: CEI ) +50% . Asta Funding (NASDAQ: ASFI ) +44% . Wright Medical Group N.V. (NASDAQ: WMGI ) +32% . Agile Therapeutics (NASDAQ: AGRX ) +31% . YRC Worldwide (NASDAQ: YRCW ) +26% . Bellicum Pharmaceuticals (NASDAQ: BLCM ) +23% . Superior...
CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
This article was selected to be shared with PRO+ subscribers - find out more here . In this article, we examine the merits of a former Business Development Company ((BDC)) that converted into a closed-end fund to invest in micro-cap companies using “constructive activism.” ...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...